TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2303613

Group type: EXPERIMENTAL
Intervention: Experiential death education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic or placebo programme
Number of subjects: 0
Study: 7385085

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette (2.6 mg nicotine, 4.5 vol percent CO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarette (0.1 mg nicotine, 1.1 vol percent CO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cigar (not inhaled)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette after beta blocker
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhalation of CO
Number of subjects: 10
Study: 31187239

Group type: EXPERIMENTAL
Intervention: Tragal cartilage perichondrium graft (Group A)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Temporal muscle fascia graft (Group B)
Number of subjects: 35
Study: 28287024

Group type: EXPERIMENTAL
Intervention: Combined training (CT) 3 times/week for 24 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study: 26296853

Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFEs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Voice Amplification (VA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 162
Study: 23498294

Group type: EXPERIMENTAL
Intervention: Lifestyle weight‐loss program (LWL)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Enhanced usual care condition (UCC)
Number of subjects: 301
Study: 22070180

Group type: EXPERIMENTAL
Intervention: Risperidone (n=40)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n=37)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medication-free subjects with autism (n=77)
Number of subjects: 21
Study: 18442947

Group type: EXPERIMENTAL
Intervention: Passive physiological movements (PPMs) for 30 min using an electrically driven bicycle
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Passive physiological movements (PPMs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no PPM)
Number of subjects: 17
Study: 17566190

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (alcohol)
Number of subjects: 12
Study: 12351525

Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: recombinant FSH + recombinant LH (rLH)
Number of subjects: 48
Study: 10825870

Group type: EXPERIMENTAL
Intervention: Ultraviolet light‐cured composite materials
Number of subjects: 130
Study: 7565419

Group type: EXPERIMENTAL
Intervention: I.V. propofol 2.5 mg/kg (G1, G3, G5)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg (G2, G4, G6)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg (G1, G2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg (G3, G4)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg followed by propofol or thiopental (G5, G6)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (G1-G6)
Number of subjects: 72
Study: 2405779

Group type: EXPERIMENTAL
Intervention: Ranimustine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 77
Study: 465920

Group type: EXPERIMENTAL
Intervention: Contrast medium containing 53 mg iodine/kg body weight
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Contrast medium containing 75 mg iodine/kg body weight
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Contrast medium containing 106 mg iodine/kg body weight
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Contrast medium containing 150 mg iodine/kg body weight
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Infusion technique over 3-8 hours
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Higher dosage regimen (106 mg and 150 mg iodine/kg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Side effects of IVC
Number of subjects: 102
Study: 31136582

Group type: EXPERIMENTAL
Intervention: TAC+EVR
Number of subjects: 40

Group type: COMPARATOR
Intervention: TAC+MMF
Number of subjects: 40
Study: 28230784

Group type: EXPERIMENTAL
Intervention: Whole Grains (WG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Refined Grains (RG)
Number of subjects: 0
Study: 25559090

Group type: EXPERIMENTAL
Intervention: Group-based memory rehabilitation programme (10 weekly sessions)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study: 23667649

Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 66

Group type: COMPARATOR
Intervention: Overweight women
Number of subjects: 66
Study: 21832026

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (52.25 μmol)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 19298097

Group type: EXPERIMENTAL
Intervention: Vermedx Diabetes Information System (DIS)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1023
Study: 17512355

Group type: EXPERIMENTAL
Intervention: Statin and statin-ezetimibe interventions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 80 mg/day of statins
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LDL lowering
Number of subjects: 57

Group type: COMPARATOR
Intervention: Statin therapies
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LDL reduction (20% to 60%)
Number of subjects: 57
Study: 15161680

Group type: EXPERIMENTAL
Intervention: GM-CSF (80 microg/day for 4 consecutive days) at each immunization
Number of subjects: 24

Group type: COMPARATOR
Intervention: Recombinant CEA alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anti-CEA IgG titers
Number of subjects: 24
Study: 11297894

Group type: EXPERIMENTAL
Intervention: Stamped return envelopes
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Business reply envelopes
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Comparison of response rates
Number of subjects: 3000
Study: 9495264

Group type: EXPERIMENTAL
Intervention: CNP (2 pmol/kg per minute for 1 hour)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CNP (4 pmol/kg per minute for 1 hour)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7980076

Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: nifedipine retard 20 mg
Number of subjects: 40
Study: 2647192

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.12% mouth rinse
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31791665

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 44
Study: 29318421

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team assessment and multimodal intervention (TEAM)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401
Study: 28216842

Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 45
Study: 25673574

Group type: EXPERIMENTAL
Intervention: PHA/BI plus CO
Number of subjects: 185

Group type: COMPARATOR
Intervention: CO only
Number of subjects: 185

Group type: COMPARATOR
Intervention: PHA/BI only
Number of subjects: 185

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 185
Study: 22102140

Group type: EXPERIMENTAL
Intervention: Pain expectation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-analgesia expectation
Number of subjects: 0
Study: 21045724

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18584971

Group type: EXPERIMENTAL
Intervention: Positive frame smoking cessation message emphasizing benefits of quitting
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Negative frame smoking cessation message emphasizing costs of not quitting
Number of subjects: 151
Study: 15465618

Group type: EXPERIMENTAL
Intervention: Dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11261828

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 9676471

Group type: EXPERIMENTAL
Intervention: Oral tenoxicam 40 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous tenoxicam 40 mg
Number of subjects: 25
Study: 7833497

Group type: EXPERIMENTAL
Intervention: Gliclazide, 80 mg twice daily for 5 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin at 50 microU/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin at 5 microU/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gliclazide treatment
Number of subjects: 0
Study: 3056045

Group type: EXPERIMENTAL
Intervention: Viscoelastic polymer insole
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Standard mesh insole
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Age of shoes
Number of subjects: 3025

Group type: COMPARATOR
Intervention: History of physical activity
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Racial background (White vs Black recruits)
Number of subjects: 3025
Study: 31079243

Group type: EXPERIMENTAL
Intervention: Subgingival ultrasonic debridement with low-concentrated hypochlorite/amino acid gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ultrasonic debridement only
Number of subjects: 32
Study: 30360969

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg orally once daily for 16 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo orally once daily for 16 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 27544583

Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition (Ex + N)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Exercise only (Ex)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 139
Study: 24374088

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 21761263

Group type: EXPERIMENTAL
Intervention: Postexperimental inquiries (PEI) administered as a computer survey with a reward offered
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postexperimental inquiries (PEI) administered as a face-to-face interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postexperimental inquiries (PEI) without any specific intervention
Number of subjects: 0
Study: 20670666

Group type: EXPERIMENTAL
Intervention: High-fat drink
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-fat drink with orlistat
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sucrose drink
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sucrose drink with acarbose
Number of subjects: 24
Study: 18571267

Group type: EXPERIMENTAL
Intervention: 90% anaerobic threshold (AT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 110% anaerobic threshold (AT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control session (CON)
Number of subjects: 11
Study: 15965424

Group type: EXPERIMENTAL
Intervention: 12-week alefacept treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 16-week alefacept treatment
Number of subjects: 20
Study: 11490696

Group type: EXPERIMENTAL
Intervention: Small access incision with minimal reflection of the mucoperiosteum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard mucoperiosteal flap
Number of subjects: 20
Study: 9924833

Group type: EXPERIMENTAL
Intervention: Stimulation-retreat model intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control unit care
Number of subjects: 97
Study: 8067226

Group type: EXPERIMENTAL
Intervention: Heparin-coated equipment (CBAS) with reduced i.v. heparin (1.5 mg.kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncoated equipment with full heparinization (3 mg.kg‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 3377061

Group type: EXPERIMENTAL
Intervention: Hydron zero‐6 lenses (38% nominal water content)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocurve II lenses (55% nominal water content)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Permalens contact lenses (71% nominal water content)
Number of subjects: 9
Study: 30608613

Group type: EXPERIMENTAL
Intervention: Chosen by the proposer (choice mode)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random pairing mode (computer selection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fair offers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfair offers to rivals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Offers received by participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivals receiving fair shares after being chosen by the proposer
Number of subjects: 0
Study: 27505301

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST) 10-day
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST) 14-day
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Concomitant Therapy (CT) 10-day
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Concomitant Therapy (CT) 14-day
Number of subjects: 341
Study: 25129681

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg first dose, followed by 2 mg/kg/d in 2 divided doses for 3 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 23312076

Group type: EXPERIMENTAL
Intervention: High-MUFA dietary portfolio
Number of subjects: 16
Study: 21067319

Group type: EXPERIMENTAL
Intervention: Bougie-assisted intubation (BAI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional endotracheal intubation (ETI)
Number of subjects: 35
Study: 18806939

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (standard technique with endoscope magnification)
Number of subjects: 72
Study: 16448970

Group type: EXPERIMENTAL
Intervention: Study diagnosis of COPD based on spirometric results (FEV(1)/FVC < 0.70)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Prior diagnosis of asthma
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Prior diagnosis of chronic bronchitis or emphysema (CBE)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: No prior diagnosis of obstructive lung disease
Number of subjects: 597
Study: 15645955

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Diet and Exercise
Number of subjects: 97
Study: 11709454

Group type: EXPERIMENTAL
Intervention: Exercise treatment from a physiotherapist in primary care for 12 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (standard treatment from general practitioner including patient education and drug treatment if necessary)
Number of subjects: 201
Study: 9046220

Group type: EXPERIMENTAL
Intervention: Intravenous cholangiography (IVC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 100
Study: 7943088

Group type: EXPERIMENTAL
Intervention: Double-dose dexamethasone (10 mg intravenously every 12 hours until delivery)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 25
Study: 29752332

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27482615

Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN) 70 mg weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg once yearly
Number of subjects: 60
Study: 24342462

Group type: EXPERIMENTAL
Intervention: Ketamine (0.15 mg/kg in a 10‐minute bolus followed by continuous infusion of 6 μg/kg per minute until the end of rTMS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 22154037

Group type: EXPERIMENTAL
Intervention: Community-based group intervention (two sessions of health education 5 weeks apart)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (self-help material only)
Number of subjects: 400
Study: 19696679

Group type: EXPERIMENTAL
Intervention: Paracetamol 0.5 mg kg(‐1)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 mg kg(‐1)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Paracetamol 2 mg kg(‐1)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg kg(‐1)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 250
Study: 18212092

Group type: EXPERIMENTAL
Intervention: High-CHOEP-14
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High-CHOEP-21
Number of subjects: 139
Study: 16574783

Group type: EXPERIMENTAL
Intervention: Adult ASPD Only
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Full ASPD
Number of subjects: 178

Group type: COMPARATOR
Intervention: No CD/ASPD
Number of subjects: 178

Group type: COMPARATOR
Intervention: CD Only
Number of subjects: 178
Study: 12749492

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 1890
Study: 11128888

Group type: EXPERIMENTAL
Intervention: Lycra garments worn for 3 hours
Number of subjects: 16
Study: 8990654

Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scleral buckling (SB)
Number of subjects: 20
Study: 1450096

Group type: EXPERIMENTAL
Intervention: Disopyramide (2 mg/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mono-N-dealkylated disopyramide (2 mg/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine (0.04 mg/kg)
Number of subjects: 10
Study: 6419640

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at operating pressures of 1.3, 1.8, and 2.3 bars.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at increasing operating pressures.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at operating pressures.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Operating pressure during HFJV.
Number of subjects: 15
Study: 31528850

Group type: EXPERIMENTAL
Intervention: Two-way mobile phone intervention plus standard of care (MPI + SOC)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Standard-of-care alone (SOC)
Number of subjects: 521
Study: 29485388

Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Intervention B
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study: 26865162

Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy (up to eight sessions, each 1 hour)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Talking control
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy
Number of subjects: 54
Study: 25210836

Group type: EXPERIMENTAL
Intervention: Annual mass azithromycin treatment (3 distributions)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Biannual mass azithromycin treatment (6 distributions)
Number of subjects: 1034
Study: 22682095

Group type: EXPERIMENTAL
Intervention: PINCER intervention (pharmacist-led information technology-enabled intervention)
Number of subjects: 82
Study: 20207412

Group type: EXPERIMENTAL
Intervention: Intervention clusters (women's groups)
Number of subjects: 36113

Group type: COMPARATOR
Intervention: Control clusters (no women's groups)
Number of subjects: 36113
Study: 18067628

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times per week for 16 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vehicle cream applied three times per week for 16 weeks
Number of subjects: 43
Study: 15952199

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 300 mg/day
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 178
Study: 11923046

Group type: EXPERIMENTAL
Intervention: L-arginine (700 mg) administered four times daily during TD-GTN therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo capsules administered four times daily during TD-GTN therapy
Number of subjects: 14
Study: 9811376

Group type: EXPERIMENTAL
Intervention: 33 microM capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 330 microM capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent stimulation with capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin in candy formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lengthened inter-stimulus interval (ISI) with intermittent stimulation
Number of subjects: 0
Study: 7666103

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1,600 mg/d (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Matching placebo (n = 28)
Number of subjects: 55
Study: 2564949

Group type: EXPERIMENTAL
Intervention: recombinant pro-urokinase (rscu-PA) 80 mg (20 mg bolus followed by 60 mg infusion for 60 min)
Number of subjects: 401

Group type: COMPARATOR
Intervention: streptokinase 1.5 million IU infused over 60 min
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: recombinant pro-urokinase (rscu-PA)
Number of subjects: 401

Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 401
Study: 401690

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN), mean dose 29 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 21